Regeneron Pharmaceuticals, Inc. Stock price
Equities
REGN
US75886F1075
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
966.3 USD | +0.29% | -0.07% | +10.02% |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Mar. 25 | Regeneron Shares Down After FDA Letter Questioning Application for Potential Lymphoma Treatment | MT |
Financials (USD)
Sales 2024 * | 13.89B | Sales 2025 * | 14.91B | Capitalization | 104B |
---|---|---|---|---|---|
Net income 2024 * | 4.26B | Net income 2025 * | 4.54B | EV / Sales 2024 * | 6.84 x |
Net cash position 2024 * | 8.91B | Net cash position 2025 * | 12.78B | EV / Sales 2025 * | 6.11 x |
P/E ratio 2024 * |
26.5
x | P/E ratio 2025 * |
24.8
x | Employees | 13,450 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.74% |
Latest transcript on Regeneron Pharmaceuticals, Inc.
1 day | +0.29% | ||
1 week | -0.07% | ||
Current month | +0.02% | ||
1 month | -2.72% | ||
3 months | +10.51% | ||
6 months | +16.06% | ||
Current year | +10.02% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 64 | 88-01-07 | |
Chief Executive Officer | 71 | 88-01-07 | |
Director of Finance/CFO | 54 | 02-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Christine Poon
BRD | Director/Board Member | 71 | 10-11-11 |
Chief Executive Officer | 71 | 88-01-07 | |
Michael Brown
BRD | Director/Board Member | 82 | 91-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.27% | 0 M€ | 0.00% | - | |
7.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 966.3 | +0.29% | 314,755 |
24-03-26 | 963.6 | +0.26% | 386,837 |
24-03-25 | 961.1 | -0.64% | 322,288 |
24-03-22 | 967.2 | -0.08% | 274,406 |
24-03-21 | 968 | +0.11% | 435,147 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.02% | 104B | |
+2.56% | 108B | |
+7.77% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B | |
-5.38% | 10.36B |